Common drug review new combination product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination (Delstrigo) Merck Canada Inc. indication: a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults without past or present evidence of viral resistance to Doravirine, Lamivudine, or Tenofovir
Human immunodeficiency virus is responsible for causing HIV infection, a condition that gradually weakens the immune system. HIV is transmitted via body fluids such as blood, semen, genital secretions, and breast milk; most commonly from unprotected sexual intercourse or through sharing of contamina...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
June 2019, 2019
|
Edition: | Final (with redactions) |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references